Skip to Main content Skip to Navigation
Journal articles

Place de l’imagerie moléculaire dans la prise en charge du cancer de la prostate

Abstract : In the management of prostate cancer in recent years, innovative therapies have appeared requiring precise and reliable disease detection. In 2021, new generation imaging (PET/CT, multiparametric MRI, PET/MRI) have their place at all stages of the prostate cancer natural history to help target the lesion(s) and guide therapy and improve the results obtained. PSMA PET/CT is currently the leader in this type of imaging with a complete offer during the disease: both from diagnosis, to recurrence or in the oligo-metastatic and metastatic stage resistant to castration with a pivotal role in the PSMA theranostic approach. However, multiparametric MRI also has many detection advantages when the prostate is left in place, which suggests the potential major benefit of hybrid PSMA PET/MRI imaging.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03546721
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Friday, January 28, 2022 - 10:00:31 AM
Last modification on : Friday, September 2, 2022 - 3:24:42 PM

Identifiers

Citation

Chloé Rousseau, M. Le Thiec, B. Maucherat, M. Frindel, V. Fleury. Place de l’imagerie moléculaire dans la prise en charge du cancer de la prostate. Cancer/Radiothérapie, Elsevier Masson, 2021, 25 (6-7), pp.663-666. ⟨10.1016/j.canrad.2021.07.032⟩. ⟨inserm-03546721⟩

Share

Metrics

Record views

10